Global dextran market was valued at $526 million in 2025 and is projected to reach $914 million by 2035, registering a compound annual growth rate (CAGR) of 5.68% during the forecast period (2026–2035). The market continues to benefit from expanding applications across pharmaceutical formulations, plasma volume expanders, biotechnology research, chromatography media, drug delivery systems, and specialty industrial formulations.

Dextran, a microbial polysaccharide produced through controlled fermentation processes, has become an essential biomaterial owing to its excellent biocompatibility, biodegradability, and water solubility. The increasing adoption of biologics, biosimilars, vaccines, monoclonal antibodies, and advanced drug delivery technologies has significantly increased demand for high-purity pharmaceutical-grade dextran. Scientific literature also highlights the critical role of excipients such as dextran in enhancing stability, manufacturability, and delivery performance of therapeutic biologics.¹

The research-based pharmaceutical sector continues to invest heavily in innovation and manufacturing capabilities. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the European pharmaceutical industry directly employs more than 940,000 people, reflecting sustained investment in advanced pharmaceutical production and specialty ingredients.² Additionally, the growing penetration of biosimilars and biologics across OECD countries is driving consumption of high-quality pharmaceutical excipients and fermentation-derived polymers.

Healthcare and pharmaceutical applications remain the largest revenue-generating segment, while biotechnology and life science research are emerging as high-growth areas due to increasing investments in cell therapy, vaccine manufacturing, and protein purification technologies. Rising demand from pharmaceutical manufacturers in Asia-Pacific, combined with expanding biotechnology infrastructure in North America and Europe, is expected to support long-term market expansion.

Market Dynamics

Driver: Growing Biopharmaceutical Manufacturing and Demand for High-Performance Pharmaceutical Excipients

The rapid expansion of the global biopharmaceutical industry is one of the primary factors driving growth in the dextran market. The increasing commercialization of monoclonal antibodies, recombinant proteins, vaccines, biosimilars, and cell and gene therapies has created substantial demand for specialty excipients capable of maintaining formulation stability and enhancing drug delivery performance. Recent studies on therapeutic biological products emphasize that excipients are indispensable components for preserving protein integrity and ensuring product efficacy throughout manufacturing and storage.¹

Furthermore, OECD data indicate continuous growth in biosimilar adoption across developed healthcare systems, increasing demand for advanced pharmaceutical ingredients used in injectable formulations and biologics manufacturing. The expansion of biologics manufacturing facilities in Asia-Pacific and Europe, together with investments in fermentation technologies and high-purity biopolymers, is expected to accelerate dextran consumption. During 2025 and 2026, manufacturers have also focused on expanding pharmaceutical-grade production capacities, strengthening quality assurance systems, and improving molecular weight consistency to meet stringent regulatory requirements and support next-generation biologic formulations.

Challenge: Limited Manufacturing Base and High Production Costs Create Supply Constraints

Despite favorable long-term demand fundamentals, the dextran market faces challenges associated with a concentrated manufacturing landscape and technically complex production processes. Pharmaceutical-grade dextran requires microbial fermentation under highly controlled Good Manufacturing Practice (GMP) conditions followed by extensive purification, molecular weight standardization, and quality testing. These requirements significantly increase production costs and create substantial barriers to market entry.

Raw material price fluctuations, fermentation feedstock availability, and energy costs continue to influence production economics. Additionally, regulatory compliance for injectable pharmaceutical applications necessitates strict control over endotoxin levels, molecular weight distribution, and impurity profiles, increasing operational expenditures for manufacturers. The global pharmaceutical supply chain's dependence on specialized ingredient producers further contributes to procurement risks and longer lead times.

To address these challenges, manufacturers are investing in process optimization, continuous fermentation technologies, automation, and advanced purification systems to improve production efficiency while maintaining regulatory compliance. Strategic collaborations with pharmaceutical companies and biotechnology firms are also helping producers secure long-term supply agreements and stabilize demand across healthcare and research applications.

Market Segmentation

• Based on the Product Type, the market is segmented into Dextran 40, Dextran 20, Dextran 60, Dextran 70, and Other (Dextran 110, Dextran 150+, and Specialty High-Viscosity Grades for Industrial Use).
• Based on the Application, the market is segmented into Healthcare & Pharmaceuticals, Food & Beverage, Biotechnology & Research, and Industrial Application.

Healthcare & Pharmaceuticals Segment Leads the Global Dextran Market

The Healthcare & Pharmaceuticals segment accounted for the largest share of the global dextran market in 2025 and is expected to maintain its dominance throughout the forecast period. Dextran is extensively used as a plasma volume expander, pharmaceutical excipient, stabilizing agent, anticoagulant additive, and drug delivery polymer in injectable formulations. Its excellent biocompatibility, low toxicity, and biodegradability have made it an indispensable component in numerous medical and pharmaceutical applications.

The increasing prevalence of chronic diseases, expanding biologics production, and rising investments in advanced therapeutics continue to drive demand for pharmaceutical-grade dextran. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), Europe remains one of the world's largest pharmaceutical manufacturing hubs, with sustained investments in research, development, and production infrastructure. Likewise, growth in biosimilar approvals and biologic manufacturing across North America and Asia-Pacific has increased the consumption of specialty excipients and fermentation-derived polysaccharides.

Between 2022 and 2026, leading manufacturers have focused on enhancing production capabilities for high-purity dextran grades suitable for injectable drugs, biotechnology applications, and advanced drug delivery systems. Investments in GMP-certified manufacturing facilities, quality assurance programs, and molecular weight standardization technologies have further strengthened the position of the healthcare segment as the primary revenue contributor to the global dextran market.

Biotechnology & Research Segment to Record Strong Growth

The Biotechnology & Research segment is anticipated to register the fastest growth during the forecast period owing to the rapid expansion of biopharmaceutical manufacturing, cell and gene therapy research, vaccine development, and protein purification technologies. Dextran-based materials are increasingly utilized in chromatography media, biomolecule separation processes, cell culture applications, nanoparticle synthesis, and tissue engineering research.

Growing investments in life sciences and precision medicine are accelerating demand for high-performance laboratory reagents and specialty biopolymers. The increasing number of biotechnology startups, contract development and manufacturing organizations (CDMOs), and academic research institutions has created new opportunities for dextran manufacturers supplying research-grade and pharmaceutical-grade materials.

From 2022 to 2026, industry participants have invested in advanced fermentation technologies, ultra-high-purity production processes, and customized molecular weight formulations to address evolving biotechnology requirements. The growing adoption of monoclonal antibodies, recombinant proteins, and personalized medicines is expected to further increase demand for dextran in purification and downstream processing applications. Continuous innovation in bioprocessing technologies and expanding investments in biotechnology infrastructure across developed and emerging economies are likely to support the segment's robust growth trajectory through 2035.

Regional Outlook

The global Dextran market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

North America represents a significant market due to its advanced pharmaceutical manufacturing capabilities, established biotechnology sector, and strong research ecosystem. Europe continues to be a major contributor owing to its mature pharmaceutical industry, robust regulatory framework, and leadership in biologics production. Asia-Pacific is projected to witness the highest growth during the forecast period, driven by expanding pharmaceutical manufacturing, increasing investments in biotechnology research, favorable government initiatives, and the growing presence of contract manufacturing organizations. Meanwhile, Latin America and the Middle East & Africa are expected to experience gradual market expansion supported by improvements in healthcare infrastructure and rising pharmaceutical production capacities.

United States Leads the Market

The United States remains the largest national market for dextran, supported by its globally competitive pharmaceutical and biotechnology industries. The country hosts numerous biopharmaceutical manufacturers, research institutions, and contract development organizations that utilize dextran in injectable formulations, drug delivery systems, chromatography processes, and laboratory applications.

The U.S. continues to lead global biopharmaceutical innovation, with substantial investments in biologics, cell therapy, and advanced manufacturing technologies. Strong regulatory oversight and a well-developed healthcare ecosystem have encouraged the adoption of high-purity pharmaceutical excipients, supporting sustained demand for dextran. The expansion of biosimilar development, precision medicine, and advanced therapeutic products is expected to further strengthen market growth over the coming decade. Continuous investments in biotechnology infrastructure and pharmaceutical R&D are likely to maintain the country's leadership position within the global dextran industry.

China to Record Strong Growth

China is expected to register the fastest growth in the global dextran market during the forecast period due to rapid expansion of its pharmaceutical manufacturing sector, biotechnology industry, and fermentation-based chemical production capabilities. The country has emerged as one of the world's leading producers of pharmaceutical intermediates and specialty biochemical ingredients, supported by large-scale industrial investments and expanding export activities.

Government initiatives promoting domestic biopharmaceutical innovation, increasing healthcare expenditure, and growing investments in biologics manufacturing facilities continue to create favorable market conditions for dextran producers. The expansion of biotechnology parks, contract manufacturing organizations, and life science research institutions has significantly increased demand for chromatography materials and specialty polysaccharides. Furthermore, China's strong manufacturing ecosystem and cost-efficient production capabilities position the country as an important supplier to global pharmaceutical and biotechnology value chains, supporting sustained growth through 2035.

Competitive Landscape

The global dextran market is characterized by moderate consolidation, with a limited number of specialized manufacturers supplying pharmaceutical-grade, biotechnology-grade, and industrial dextran products. Competition is primarily based on product purity, molecular weight consistency, regulatory compliance, production technology, and long-term supply reliability. Companies are increasingly investing in fermentation process optimization, advanced purification technologies, and customized product development to address evolving customer requirements across healthcare and biotechnology applications.

Leading market participants are expanding their manufacturing capacities while strengthening research and development capabilities to support next-generation biologics, cell therapy, and protein purification applications. Strategic collaborations with pharmaceutical manufacturers, biotechnology companies, and academic research organizations continue to enhance product innovation and global distribution networks.

Major companies operating in the global dextran market include Cytiva (Danaher), which maintains a strong position through its extensive life sciences and bioprocessing portfolio; Fujifilm Wako Pure Chemical Corporation, recognized for high-quality research chemicals and laboratory reagents; Merck KGaA (Sigma-Aldrich), a leading supplier of pharmaceutical and biotechnology-grade specialty chemicals; Pharmacosmos A/S, known for its expertise in iron-carbohydrate technologies and dextran-based pharmaceutical products; and Thermo Fisher Scientific, which offers a broad portfolio of life science reagents and specialty biochemical materials supporting pharmaceutical research and industrial biotechnology applications. Continuous innovation, regulatory compliance, and global supply chain capabilities remain the key competitive differentiators shaping the industry's long-term growth.

Recent Developments

• Pharmacosmos A/S introduced Pharmaceutical-Quality DEAE-Dextran with GMP certification. The launch expanded the company's portfolio of pharmaceutical-grade dextran derivatives for vaccine adjuvants, gene therapy, and transfection applications. This strategic expansion strengthens Pharmacosmos' leadership in high-purity dextran solutions while addressing increasing regulatory requirements and demand from advanced biologics manufacturers.
• FUJIFILM Wako Pure Chemical Corporation expanded its engagement with the life science research community through specialized cell culture and biotechnology initiatives. The company's continued investment in research reagents and laboratory solutions supports increasing demand from regenerative medicine and biotechnology applications, reinforcing its position in the specialty biochemical market.
• Thermo Fisher Scientific expanded its microbial bioprocessing portfolio with new chemically defined media for recombinant protein and plasmid DNA production. The expansion aims to improve manufacturing consistency for biologics and gene therapy products, indirectly strengthening demand for complementary specialty biomaterials used in downstream bioprocessing applications.
• 2025 – Thermo Fisher Scientific continued expanding its global bioprocessing and advanced therapy infrastructure through new collaboration centers and capacity additions. The investment supports cell and gene therapy developers by improving process development capabilities and accelerating commercialization, thereby enhancing the broader ecosystem utilizing specialty biopolymers and purification materials.
• Pharmacosmos reinforced its position as a leading pharmaceutical dextran supplier by expanding its portfolio of specialty carbohydrate products manufactured through solvent-free production technology. The initiative supports sustainability objectives while providing pharmaceutical manufacturers with high-purity dextran derivatives suitable for vaccines, cryopreservation, ophthalmic products, and protein stabilization applications.
• Advances in enzymatic dextran synthesis technology demonstrated the potential for more efficient production of medium molecular weight dextran grades widely used in pharmaceutical applications. These developments are expected to improve production efficiency, molecular weight control, and future commercial scalability for biomedical and biotechnology applications.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global Dextran market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying "who-stands-where" in the market.
• Market assessment by product type, application, and regional outlook with qualitative and quantitative insights.
• Evaluation of key growth drivers, restraints, opportunities, technological advancements, and competitive developments influencing the industry through 2035.